Cipamfylline

Drug Profile

Cipamfylline

Alternative Names: BRL 61063; HEP 688

Latest Information Update: 13 May 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Antiallergics; Antiasthmatics; Antineoplastics; Antivirals; Xanthines
  • Mechanism of Action Tumour necrosis factor inhibitors; Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Atopic dermatitis; Viral infections

Most Recent Events

  • 13 May 2003 Cipamfylline is no longer licensed to LEO Pharma
  • 13 May 2003 Discontinued - Phase-II for Atopic dermatitis in Canada (Topical)
  • 13 May 2003 Discontinued - Phase-II for Atopic dermatitis in Europe (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top